Evaluation of Subcutaneous (SC) Injected Tc 99m Tilmanocept Localization in Active Rheumatoid Arthritis (RA) Subjects by SPECT and SPECT/CT Imaging
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2018
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Navidea Biopharmaceuticals
- 16 Jun 2018 Results assessing Tc 99M Tilmanocept Localization in Active Rheumatoid Arthritis (Ra) Subjects by Planar and Spect/Ct, presented at the 19th Annual Congress of the European League Against Rheumatism
- 14 Dec 2016 Status changed from recruiting to completed.
- 03 Nov 2016 According to a Navidea Biopharmaceuticals media release, to date, 17 of 18 patients have been dosed and imaged in the study.